# TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT06082635** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 321 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** TGRX-326
- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT06082635
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-14
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06082635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06082635, "TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06082635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*